Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

Fig. 2

Proportions of patients with (a) overall, clinical, and MRI NEDA maintained over 2 years, and (b) no relapses, no confirmed disability worsening, and no MRI lesions over 2 years. Patients missing measurements who achieved NEDA on all available measurements were excluded, whereas patients missing measurements who had evidence of disease activity on ≥1 measurement were considered as not achieving NEDA. CI = confidence interval; EDSS = Expanded Disability Status Scale; MRI = magnetic resonance imaging; NEDA = no evidence of disease activity

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us